GH treatment improves height growth rate in our patients, maintaining a significant efficacy along 2 years. Our results confirm that APA are detectable in CD patients with GHD suggesting an involvement of autoimmune mechanisms in the lack of height improvement after GFD. These patients could benefit by precocious hormonal therapy, interrupting the progression towards a stable clinical disease.

The effect of growth hormone (GH) treatment in children with celiac disease (CD), antipituitary antibodies (APA) and growth hormonedeficiency (GHD) / Iughetti, Lorenzo; A., De Bellis; Predieri, Barbara; A., Bellastella; A., Bizzarro; S., Madeo; L., Saviano; F., Balli; S., Bernasconi. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 64 (S4):(2006), pp. 152-152. ((Intervento presentato al convegno 45th Meeting dell’European Society of Pediatric Endocrinology, tenutosi a Rotterdam 30 giugno-3 luglio 2006, nel Rotterdam 30 giugno-3 luglio 2006,.

The effect of growth hormone (GH) treatment in children with celiac disease (CD), antipituitary antibodies (APA) and growth hormonedeficiency (GHD)

IUGHETTI, Lorenzo;PREDIERI, Barbara;
2006-01-01

Abstract

GH treatment improves height growth rate in our patients, maintaining a significant efficacy along 2 years. Our results confirm that APA are detectable in CD patients with GHD suggesting an involvement of autoimmune mechanisms in the lack of height improvement after GFD. These patients could benefit by precocious hormonal therapy, interrupting the progression towards a stable clinical disease.
64 (S4)
152
152
Iughetti, Lorenzo; A., De Bellis; Predieri, Barbara; A., Bellastella; A., Bizzarro; S., Madeo; L., Saviano; F., Balli; S., Bernasconi
The effect of growth hormone (GH) treatment in children with celiac disease (CD), antipituitary antibodies (APA) and growth hormonedeficiency (GHD) / Iughetti, Lorenzo; A., De Bellis; Predieri, Barbara; A., Bellastella; A., Bizzarro; S., Madeo; L., Saviano; F., Balli; S., Bernasconi. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 64 (S4):(2006), pp. 152-152. ((Intervento presentato al convegno 45th Meeting dell’European Society of Pediatric Endocrinology, tenutosi a Rotterdam 30 giugno-3 luglio 2006, nel Rotterdam 30 giugno-3 luglio 2006,.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/742616
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact